Onsera Health launches AI platform for cardiometabolic care

Onsera Health has emerged from stealth to sell an AI-driven cardiometabolic and weight management platform to employers, health plans and union trusts. The company says the model is designed to improve GLP-1 outcomes, reduce downstream claims and control costs through personalized clinical oversight and longitudinal monitoring.

Why it matters: - Employers, health plans and union trusts are under pressure to manage rising GLP-1 spending while still offering access to weight-loss drugs. - Onsera Health is positioning a structured care model as a way to improve adherence, reduce weight regain and lower total medical costs. - The company is targeting cardiometabolic disease earlier in the care pathway, where it says intervention can improve outcomes over time.

What happened: - Onsera Health emerged from stealth on June 9, 2026, in New York. - The company launched a comprehensive, AI-driven cardiometabolic and weight management platform for employers, health plans and union trusts. - Onsera Health says the platform is already working with self-funded employers and trusts. - Dr. Kristin Baier, chief medical officer, said GLP-1 therapies work best inside a connected system designed to manage outcomes, costs and patient experience over time. - Jeff Bernhard, CEO, said the company was built to help employers and health plans maintain access to breakthrough medications while controlling costs.

The details: - Onsera Health combines clinical AI simulation with structured medical oversight. - The model is designed to manage GLP-1 therapies for lasting weight loss and improved health outcomes. - The platform integrates analytics, clinical protocols and coordinated care pathways. - Onsera Health says the approach is intended to improve adherence, optimize outcomes and reduce downstream healthcare and productivity costs. - The care model includes clinician-guided access to GLP-1 therapies with direct manufacturer pricing. - Clinical oversight is led by obesity-trained, board-certified physicians, registered nurses, labs, biometric devices, registered dietitians and health coaches. - The platform also includes behavioral and nutritional support aligned with medication treatment. - Onsera Health says the care model supports transitions from intensive medication phases to long-term metabolic stability to help prevent weight regain. - The company includes longitudinal monitoring of medication adherence and physiological response. - Outcomes measurement covers workforce health metrics, total cost of care and performance against expected value.

Between the lines: - Onsera Health is betting that employers and payers will value measurable outcomes over drug cost alone. - The company’s pitch reflects a broader shift in obesity care toward hybrid virtual models that combine medication, behavior change and ongoing monitoring. - The company cites clinical trial results showing average weight loss of 15% to 22% and up to 20% reduction in cardiovascular events, but says real-world results often fall short without structured support. - High discontinuation rates tied to side effects, cost barriers and limited clinical support remain a key obstacle for GLP-1 programs. - Onsera Health has assembled a Clinical Advisory Board that includes Sir John Bell, Dr. Robert Califf, Dr. Gary Foster, Dr. Melanie Jay, Dr. Ian Neeland and Dr. Robert Stoekenbroek. - Dr. Melanie Jay said Onsera built the clinical infrastructure needed to turn medication into lasting health outcomes for patients and employers.

What’s next: - Onsera Health will attend SHRM26 in Orlando from June 16-19. - The company will staff exhibitor booth #1136 at the event. - Dr. Kristin Baier is scheduled to speak on June 18 at 1 p.m. ET in the exhibit theater on a session titled “A GLP-1 & Weight Management Benefit That Works: Driving Outcomes, Reducing Risk, and Lowering Costs.” - Onsera Health directs readers to more information.

The bottom line: - Onsera Health is trying to make GLP-1 programs more predictable for employers by wrapping the drugs in a full clinical and analytics layer.